Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2022 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10451/58080 |
Resumo: | Copyright © 2022 Cruz-Machado, Barreira, Bandeira, Veldhoen, Gomes, Serrano, Duarte, Rato, Miguel Fernandes, Garcia, Pinheiro, Bernardes, Madeira, Miguel, Torres, Bento Silva, Pestana, Almeida, Mazeda, Cunha Santos, Pinto, Sousa, Parente, Sequeira, Santos, Fonseca and Romão. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| id |
RCAP_39955d196b323bca618891590a1ceb82 |
|---|---|
| oai_identifier_str |
oai:repositorio.ul.pt:10451/58080 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide studyCOVID-19SARS-CoV-2Antibody responseInflammatory rheumatic diseasesSeroconversionCopyright © 2022 Cruz-Machado, Barreira, Bandeira, Veldhoen, Gomes, Serrano, Duarte, Rato, Miguel Fernandes, Garcia, Pinheiro, Bernardes, Madeira, Miguel, Torres, Bento Silva, Pestana, Almeida, Mazeda, Cunha Santos, Pinto, Sousa, Parente, Sequeira, Santos, Fonseca and Romão. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Objective: To identify risk factors for SARS-CoV-2 infection and for severe/critical COVID-19, and to assess the humoral response after COVID-19 in these patients. Methods: Nationwide study of adult patients with inflammatory RMDs prospectively followed in the Rheumatic Diseases Portuguese Register-Reuma.pt-during the first 6 months of the pandemic. We compared patients with COVID-19 with those who did not develop the disease and patients with mild/moderate disease with those exhibiting severe/critical COVID-19. IgG antibodies against SARS-CoV-2 were measured ≥3 months after infection and results were compared with matched controls. Results: 162 cases of COVID-19 were registered in a total of 6,363 appointments. Patients treated with TNF inhibitors (TNFi; OR = 0.160, 95% CI 0.099-0.260, P < 0.001) and tocilizumab (OR 0.147, 95% CI 0.053-0.408, P < 0.001) had reduced odds of infection. Further, TNFi tended to be protective of severe and critical disease. Older age, major comorbidities, and rituximab were associated with an increased risk of infection and worse prognosis. Most patients with inflammatory RMDs (86.2%) developed a robust antibody response. Seroconversion was associated with symptomatic disease (OR 13.46, 95% CI 2.21-81.85, P = 0.005) and tended to be blunted by TNFi (OR 0.17, 95% CI 0.03-1.05; P = 0.057). Conclusions: TNFi and tocilizumab reduced the risk of infection by SARS-CoV-2. Treatment with TNFi also tended to reduce rates of severe disease and seroconversion. Older age, general comorbidities and rituximab were associated with increased risk for infection and worse prognosis, in line with previous reports. Most patients with RMDs developed a proper antibody response after COVID-19, particularly if they had symptomatic disease.We acknowledge the generous sharing of the expression constructs by Dr. Florian Krammer, Icahn School of Medicine at Mount Sinai, New York, USA [Development of SARS-CoV-2 reagents was partially supported by the NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract HHSN272201400008C] and the protein production by Drs. Paula Alves and Rute Castro at Instituto de Biologia Experimental e Tecnológica (iBET) Oeiras, Portugal as part of the Serology COVID consortium.FrontiersRepositório da Universidade de LisboaMachado, Ana RitaBarreira, SofiaBandeira, MatildeVeldhoen, MarcGomes, AndreiaSerrano, MartaDuarte, CatarinaRato, MariaMiguel Fernandes, BrunoGarcia, SaloméPinheiro, FilipeBernardes, MiguelMadeira, NathalieMiguel, CláudiaTorres, RitaBento Silva, AnaPestana, JorgeAlmeida, DiogoMazeda, CarolinaCunha Santos, FilipePinto, PatríciaSousa, MarleneParente, HugoSequeira, GraçaSantos, Maria JoséFonseca, João EuricoRomão, Vasco C.2023-06-07T14:43:51Z20222022-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/58080engFront Med (Lausanne). 2022 Jun 13;9:90181710.3389/fmed.2022.9018172296-858Xinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T17:06:43Zoai:repositorio.ul.pt:10451/58080Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T22:08:22.001787Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| title |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| spellingShingle |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study Machado, Ana Rita COVID-19 SARS-CoV-2 Antibody response Inflammatory rheumatic diseases Seroconversion |
| title_short |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| title_full |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| title_fullStr |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| title_full_unstemmed |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| title_sort |
Risk factors for infection, predictors of severe disease, and antibody response to COVID-19 in patients with inflammatory rheumatic diseases in Portugal: a multicenter, nationwide study |
| author |
Machado, Ana Rita |
| author_facet |
Machado, Ana Rita Barreira, Sofia Bandeira, Matilde Veldhoen, Marc Gomes, Andreia Serrano, Marta Duarte, Catarina Rato, Maria Miguel Fernandes, Bruno Garcia, Salomé Pinheiro, Filipe Bernardes, Miguel Madeira, Nathalie Miguel, Cláudia Torres, Rita Bento Silva, Ana Pestana, Jorge Almeida, Diogo Mazeda, Carolina Cunha Santos, Filipe Pinto, Patrícia Sousa, Marlene Parente, Hugo Sequeira, Graça Santos, Maria José Fonseca, João Eurico Romão, Vasco C. |
| author_role |
author |
| author2 |
Barreira, Sofia Bandeira, Matilde Veldhoen, Marc Gomes, Andreia Serrano, Marta Duarte, Catarina Rato, Maria Miguel Fernandes, Bruno Garcia, Salomé Pinheiro, Filipe Bernardes, Miguel Madeira, Nathalie Miguel, Cláudia Torres, Rita Bento Silva, Ana Pestana, Jorge Almeida, Diogo Mazeda, Carolina Cunha Santos, Filipe Pinto, Patrícia Sousa, Marlene Parente, Hugo Sequeira, Graça Santos, Maria José Fonseca, João Eurico Romão, Vasco C. |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Machado, Ana Rita Barreira, Sofia Bandeira, Matilde Veldhoen, Marc Gomes, Andreia Serrano, Marta Duarte, Catarina Rato, Maria Miguel Fernandes, Bruno Garcia, Salomé Pinheiro, Filipe Bernardes, Miguel Madeira, Nathalie Miguel, Cláudia Torres, Rita Bento Silva, Ana Pestana, Jorge Almeida, Diogo Mazeda, Carolina Cunha Santos, Filipe Pinto, Patrícia Sousa, Marlene Parente, Hugo Sequeira, Graça Santos, Maria José Fonseca, João Eurico Romão, Vasco C. |
| dc.subject.por.fl_str_mv |
COVID-19 SARS-CoV-2 Antibody response Inflammatory rheumatic diseases Seroconversion |
| topic |
COVID-19 SARS-CoV-2 Antibody response Inflammatory rheumatic diseases Seroconversion |
| description |
Copyright © 2022 Cruz-Machado, Barreira, Bandeira, Veldhoen, Gomes, Serrano, Duarte, Rato, Miguel Fernandes, Garcia, Pinheiro, Bernardes, Madeira, Miguel, Torres, Bento Silva, Pestana, Almeida, Mazeda, Cunha Santos, Pinto, Sousa, Parente, Sequeira, Santos, Fonseca and Romão. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| publishDate |
2022 |
| dc.date.none.fl_str_mv |
2022 2022-01-01T00:00:00Z 2023-06-07T14:43:51Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/58080 |
| url |
http://hdl.handle.net/10451/58080 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
Front Med (Lausanne). 2022 Jun 13;9:901817 10.3389/fmed.2022.901817 2296-858X |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Frontiers |
| publisher.none.fl_str_mv |
Frontiers |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799134638449360896 |